QUOTED. 14 October 2019. Cecilia Wolyniak.
At a recent industry meeting, US FDA recall officials emphasized that, contrary to what some device-makers may believe, there’s no requirement that recall documentation be submitted on paper, rather than electronically. See what Cecilia Wolyniak, the agency's recall team leader, said about it here.
You may also be interested in...
Officials in the US FDA's recall divisions advised manufacturers on the best ways to work with the agency during the recalls process, including keeping track of who they're speaking with, making sure all required forms are complete, and not being afraid to use eSubmit.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.